Unicycive Resubmits OLC NDA with New Manufacturing Vendor, Adds Commercial Veteran to Board
UNCY sits 32% above its 52-week low of $3.75.
Summary
Unicycive resubmitted its OLC NDA with CMC data from a new manufacturing vendor that passed FDA inspection, and appointed commercial veteran Meredith Manning to its board.
Key Events · Product Development and Regulatory · UNCY
-
OLC NDA Resubmitted with New Vendor
Resubmission includes CMC data from a new third-party manufacturer whose facility received 'No Action Indicated' status from FDA in March 2024, addressing the deficiencies cited in two prior CRLs.
-
Regulatory Timeline Set
Company anticipates FDA acceptance within 30 days and a new PDUFA date six months from resubmission; original vendor's reinspection is still pending and could accelerate approval if favorable.
-
Cash Runway Extended
As of June 30, 2026, cash and marketable securities totaled $61.4 million, supporting OLC commercial launch preparation and runway into the second half of 2027.
-
Commercial Veteran Joins Board
Meredith S. Manning appointed independent director effective October 1, 2026; she led U.S. launches of VYKAT XR at Soleno and BESREMi at PharmaEssentia, and will chair the Nominating and Corporate Governance Committee.
Analysis · UNCY · Life Sciences
Unicycive has resubmitted its NDA for oxylanthanum carbonate (OLC) using a new third-party manufacturing vendor whose facility received a clean 'No Action Indicated' FDA inspection in March 2024. This directly addresses the manufacturing deficiencies that triggered two prior Complete Response Letters. The company expects FDA acceptance within 30 days and a PDUFA date six months from resubmission. Separately, the board added Meredith Manning, a seasoned biopharma commercial executive who led the U.S. launch of VYKAT XR at Soleno and BESREMi at PharmaEssentia, effective October 1, 2026. The resubmission is a concrete regulatory step toward potential approval of the company's lead asset, and the board appointment strengthens commercial readiness ahead of a possible launch.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.7% of the 1013 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, UNCY was trading at $4.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $129.2M. The 52-week trading range was $3.75 to $8.74. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.